MLXIPL and gestational diabetes: AS IV treatment inhibited the reduction in equol levels, suggesting that AS IV may inhibit GDM by modulating equol levels and improve insulin secretion failure through Chrebp/Txnip signaling by modulating PKA/PP2A signaling activity.